Viking Therapeutics
VKTX
14 hedge funds and large institutions have $1.7M invested in Viking Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
57% more capital invested
Capital invested by funds: $1.08M → $1.7M (+$618K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
8% more funds holding
Funds holding: 13 → 14 (+1)
Top Buyers
| 1 |
SCM
Sio Capital Management
New York
|
+$391K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$43.7K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$31.2K |
| 4 |
Renaissance Technologies
New York
|
+$28.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.5K |
Top Sellers
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$25K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$21K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$265 |
VKTX Hedge Fund Activity: Q3 2016 in Review
14 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2016, worth a combined $1.7M — up 57% from $1.08M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VKTX positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Sio Capital Management, adding an estimated $391K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $25K sold.
- 14 institutional investors held Viking Therapeutics (VKTX) as of Q3 2016, up from 13 in Q2 2016.
- Funds reported $1.7M of Viking Therapeutics stock for Q3 2016, up 57% quarter-over-quarter.
- 4 funds opened new Viking Therapeutics positions in Q3 2016 and 3 closed out, a net change of +1 holder.
- The largest Viking Therapeutics buyer in Q3 2016 was Sio Capital Management, an estimated $391K added.
- The largest Viking Therapeutics seller in Q3 2016 was A.R.T. Advisors, an estimated $25K sold.
Based on aggregated 13F filings for Q3 2016.